Ventyx Biosciences Inc VTYX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:30 PM EDT
4.38quote price arrow up+0.19 (+4.53%)
Volume
6,700
Close
4.19quote price arrow up+0.02 (+0.48%)
Volume
427,819
52 week range
1.87 - 40.58
Loading...
  • Open4.25
  • Day High4.35
  • Day Low4.11
  • Prev Close4.17
  • 52 Week High40.58
  • 52 Week High Date07/03/23
  • 52 Week Low1.87
  • 52 Week Low Date01/19/24

Key Stats

  • Market Cap295.392M
  • Shares Out70.50M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.48
  • YTD % Change69.64

KEY STATS

  • Open4.25
  • Day High4.35
  • Day Low4.11
  • Prev Close4.17
  • 52 Week High40.58
  • 52 Week High Date07/03/23
  • 52 Week Low1.87
  • 52 Week Low Date01/19/24
  • Market Cap295.392M
  • Shares Out70.50M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta0.48
  • YTD % Change69.64

RATIOS/PROFITABILITY

  • EPS (TTM)-3.24
  • P/E (TTM)-1.29
  • Fwd P/E (NTM)-1.72
  • EBITDA (TTM)-205.913M
  • ROE (TTM)-56.76%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/12/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ventyx Biosciences Inc

 

Profile

MORE
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to...
Sheila Gujrathi M.D.
Executive Chairperson of the Board
Raju Mohan Ph.D.
President, Chief Executive Officer, Founder, Director
Martin Auster M.D.
Chief Financial Officer
Address
12790 El Camino Real, Suite 200
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
INZY
Inozyme Pharma Inc
4.67+0.04+0.86%
VSTM
Verastem Inc
13.12-0.04-0.30%
OPT
Opthea Ltd
3.58-0.03-0.83%
CADL
Candel Therapeutics Inc
14.00+3.30+30.84%
ACRV
Acrivon Therapeutics Inc
8.65+0.29+3.47%